Nautilus Biotechnolgy
NAUT
42 hedge funds and large institutions have $136M invested in Nautilus Biotechnolgy in 2020 Q3 according to their latest regulatory filings, with 42 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
81.81% more ownership
Funds ownership: 0% → 81.81% (+82%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$10.7M |
| 2 |
BlackRock
New York
|
+$10.7M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$10.7M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$8.6M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$8.53M |
Top Sellers
NAUT Hedge Fund Activity: Q3 2020 in Review
42 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q3 2020, worth a combined $136M.
Buyers outnumbered sellers: 42 funds opened new NAUT positions and 0 closed out — a net gain of 42 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $10.7M.
- 42 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $136M of Nautilus Biotechnolgy stock for Q3 2020.
- 42 funds opened new Nautilus Biotechnolgy positions in Q3 2020 and 0 closed out, a net change of +42 holders.
- The largest Nautilus Biotechnolgy buyer in Q3 2020 was Bain Capital Life Sciences Investors, an estimated $10.7M added.
Based on aggregated 13F filings for Q3 2020.